1. An altered microbiota pattern precedes Type 2 diabetes mellitus development: From the CORDIOPREV study
- Author
-
Jose M. Ordovas, Niki Katsiki, Raúl M. Luque, Frank H. J. Schuren, Helena Molina-Abril, Cristina Vals-Delgado, Irene Roncero-Ramos, Antonio Camargo, Jose Lopez-Miranda, Tim J. van den Broek, Martien P. M. Caspers, Javier Delgado-Lista, Juan F. Alcala-Diaz, Pablo Perez-Martinez, Ben van Ommen, and Universidad de Sevilla. Departamento de Matemática Aplicada I (ETSII)
- Subjects
0301 basic medicine ,Medicine (General) ,Diabetes risk ,Science (General) ,endocrine system diseases ,Intestinal microbiota ,Disease ,Gut flora ,Bioinformatics ,03 medical and health sciences ,Q1-390 ,0302 clinical medicine ,R5-920 ,Diabetes mellitus ,RNA, Ribosomal, 16S ,Type 2 diabetes mellitus ,medicine ,Humans ,Microbiome ,ComputingMethodologies_COMPUTERGRAPHICS ,Multidisciplinary ,Framingham Risk Score ,biology ,business.industry ,Microbiota ,Area under the curve ,Type 2 Diabetes Mellitus ,nutritional and metabolic diseases ,CORDIOPREV ,biology.organism_classification ,medicine.disease ,Gastrointestinal Microbiome ,Coronary heart disease ,030104 developmental biology ,Diabetes Mellitus, Type 2 ,Predictive model ,030220 oncology & carcinogenesis ,Medicine ,business ,Biomarkers - Abstract
Graphical abstract, Highlights • Type 2 diabetes (T2DM) increases the risk of recurrence in myocardial infarction patients. • A gut microbiota profile is associated to the further T2DM development. • Microbiome data improved the prediction of T2DM development when added to clinical parameters. • A risk score including the most predictive genera was associated with the probability of T2DM. • A high risk score was associated with a higher hepatic insulin resistance and β-cell dysfunction., Introduction A distinctive gut microbiome have been linked to type 2 diabetes mellitus (T2DM). Objectives We aimed to evaluate whether gut microbiota composition, in addition to clinical biomarkers, could improve the prediction of new incident cases of diabetes in patients with coronary heart disease. Methods All the patients from the CORDIOPREV (Clinical Trials.gov.Identifier: NCT00924937) study without T2DM at baseline were included (n = 462). Overall, 107 patients developed it after a median of 60 months. The gut microbiota composition was determined by 16S rRNA gene sequencing and predictive models were created using hold-out method. Results A gut microbiota profile associated with T2DM development was determined through a microbiome-based predictive model. The addition of microbiome data to clinical parameters (variables included in FINDRISC risk score and the diabetes risk score of the American Diabetes Association, HDL, triglycerides and HbA1c) improved the prediction increasing the area under the curve from 0.632 to 0.946. Furthermore, a microbiome-based risk score including the ten most discriminant genera, was associated with the probability of develop T2DM. Conclusion These results suggest that a microbiota profile is associated to the T2DM development. An integrate predictive model of microbiome and clinical data that can improve the prediction of T2DM is also proposed, if is validated in independent populations to prevent this disease.
- Published
- 2021